Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy)
Abstract Immunotherapy is now widely established as a potent and effective treatment option across several types of cancer. However, there is increasing recognition that not all patients respond to immunotherapy, focusing attention on the immune contexture of the tumor microenvironment (TME), driver...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2019-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s40425-019-0798-3 |
| _version_ | 1818202442669490176 |
|---|---|
| author | Paolo A. Ascierto Carlo Bifulco Luigi Buonaguro Leisha A. Emens Robert L. Ferris Bernard A. Fox Greg M. Delgoffe Jérôme Galon Cesare Gridelli Marco Merlano Paul Nathan Kunle Odunsi Hideho Okada Chrystal M. Paulos Sandro Pignata Kurt A. Schalper Stefani Spranger Giampaolo Tortora Hassane Zarour Lisa H. Butterfield Igor Puzanov |
| author_facet | Paolo A. Ascierto Carlo Bifulco Luigi Buonaguro Leisha A. Emens Robert L. Ferris Bernard A. Fox Greg M. Delgoffe Jérôme Galon Cesare Gridelli Marco Merlano Paul Nathan Kunle Odunsi Hideho Okada Chrystal M. Paulos Sandro Pignata Kurt A. Schalper Stefani Spranger Giampaolo Tortora Hassane Zarour Lisa H. Butterfield Igor Puzanov |
| author_sort | Paolo A. Ascierto |
| collection | DOAJ |
| description | Abstract Immunotherapy is now widely established as a potent and effective treatment option across several types of cancer. However, there is increasing recognition that not all patients respond to immunotherapy, focusing attention on the immune contexture of the tumor microenvironment (TME), drivers of the immune response and mechanisms of tumor resistance to immunity. The development of novel immunotherapeutics and their use in combination with checkpoint inhibitors and other standard of care and novel treatment modalities is an area of particular attention across several tumor types, including melanoma, lung, ovarian, breast, pancreatic, renal, head and neck, brain and non-melanoma skin cancers. The 4th Immunotherapy Bridge meeting (28–29 November, 2018, Naples, Italy) focused on a wide range of evolving topics and trends in the field of cancer immunotherapy and key presentations from this meeting are summarised in this report. |
| first_indexed | 2024-12-12T03:09:31Z |
| format | Article |
| id | doaj.art-521b648e5d4848b4b2defdca6c669e8b |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-12-12T03:09:31Z |
| publishDate | 2019-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-521b648e5d4848b4b2defdca6c669e8b2022-12-22T00:40:26ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262019-11-017112010.1186/s40425-019-0798-3Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy)Paolo A. Ascierto0Carlo Bifulco1Luigi Buonaguro2Leisha A. Emens3Robert L. Ferris4Bernard A. Fox5Greg M. Delgoffe6Jérôme Galon7Cesare Gridelli8Marco Merlano9Paul Nathan10Kunle Odunsi11Hideho Okada12Chrystal M. Paulos13Sandro Pignata14Kurt A. Schalper15Stefani Spranger16Giampaolo Tortora17Hassane Zarour18Lisa H. Butterfield19Igor Puzanov20Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale Tumori IRCCS Fondazione G. PascaleEarle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical CenterCancer Immunoregulation Unit, Istituto Nazionale Tumori IRCCS Fondazione G. PascaleUPMC Hillman Cancer Center, University of PittsburghUPMC Hillman Cancer Center, University of PittsburghLaboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Center in the Earle A. Chiles Research Institute at Providence Cancer InstituteDepartment of Immunology, University of PittsburghNational Institute of Health and Medical Research, INSERM, Cordeliers Research CenterUnit of Medical Oncology, Hospital “San Giuseppe Moscati”Oncology Department, ASO Santa Croce e Carle CuneoMount Vernon Cancer CentreDepartment of Gynaecologic Oncology, Executive Director, Center for Immunotherapy, Roswell Park Comprehensive Cancer CenterDepartment of Neurological Surgery, University of California San Francisco, Parker Institute for Cancer ImmunotherapyDepartment of Microbiology and Immunology Hollings Cancer Center, Medical University of South Carolina (MUSC)Uro-Gynaecological Department, Istituto Nazionale Tumori Fondazione G. PascaleDepartment of Pathology, Yale School of Medicine, Translational Immuno-oncology Laboratory, Yale Cancer Center, Medical Oncology, Yale School of Medicine and Yale Cancer CenterThe Koch Institute for Integrative Cancer Research at MIT and Department of Biology, Massachusetts Institute of TechnologyMedical Oncology, Fondazione Policlinico Universitario GemelliMelanoma Program, University of Pittsburgh Cancer InstituteParker Institute for Cancer Immunotherapy Research Center, UCSFDepartment of Medicine, Roswell Park Comprehensive Cancer CenterAbstract Immunotherapy is now widely established as a potent and effective treatment option across several types of cancer. However, there is increasing recognition that not all patients respond to immunotherapy, focusing attention on the immune contexture of the tumor microenvironment (TME), drivers of the immune response and mechanisms of tumor resistance to immunity. The development of novel immunotherapeutics and their use in combination with checkpoint inhibitors and other standard of care and novel treatment modalities is an area of particular attention across several tumor types, including melanoma, lung, ovarian, breast, pancreatic, renal, head and neck, brain and non-melanoma skin cancers. The 4th Immunotherapy Bridge meeting (28–29 November, 2018, Naples, Italy) focused on a wide range of evolving topics and trends in the field of cancer immunotherapy and key presentations from this meeting are summarised in this report.http://link.springer.com/article/10.1186/s40425-019-0798-3ImmunotherapyCheckpoint inhibitorsCombination therapyBiomarkersTumor microenvironment |
| spellingShingle | Paolo A. Ascierto Carlo Bifulco Luigi Buonaguro Leisha A. Emens Robert L. Ferris Bernard A. Fox Greg M. Delgoffe Jérôme Galon Cesare Gridelli Marco Merlano Paul Nathan Kunle Odunsi Hideho Okada Chrystal M. Paulos Sandro Pignata Kurt A. Schalper Stefani Spranger Giampaolo Tortora Hassane Zarour Lisa H. Butterfield Igor Puzanov Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy) Journal for ImmunoTherapy of Cancer Immunotherapy Checkpoint inhibitors Combination therapy Biomarkers Tumor microenvironment |
| title | Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy) |
| title_full | Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy) |
| title_fullStr | Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy) |
| title_full_unstemmed | Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy) |
| title_short | Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy) |
| title_sort | perspectives in immunotherapy meeting report from the immunotherapy bridge 2018 28 29 november 2018 naples italy |
| topic | Immunotherapy Checkpoint inhibitors Combination therapy Biomarkers Tumor microenvironment |
| url | http://link.springer.com/article/10.1186/s40425-019-0798-3 |
| work_keys_str_mv | AT paoloaascierto perspectivesinimmunotherapymeetingreportfromtheimmunotherapybridge20182829november2018naplesitaly AT carlobifulco perspectivesinimmunotherapymeetingreportfromtheimmunotherapybridge20182829november2018naplesitaly AT luigibuonaguro perspectivesinimmunotherapymeetingreportfromtheimmunotherapybridge20182829november2018naplesitaly AT leishaaemens perspectivesinimmunotherapymeetingreportfromtheimmunotherapybridge20182829november2018naplesitaly AT robertlferris perspectivesinimmunotherapymeetingreportfromtheimmunotherapybridge20182829november2018naplesitaly AT bernardafox perspectivesinimmunotherapymeetingreportfromtheimmunotherapybridge20182829november2018naplesitaly AT gregmdelgoffe perspectivesinimmunotherapymeetingreportfromtheimmunotherapybridge20182829november2018naplesitaly AT jeromegalon perspectivesinimmunotherapymeetingreportfromtheimmunotherapybridge20182829november2018naplesitaly AT cesaregridelli perspectivesinimmunotherapymeetingreportfromtheimmunotherapybridge20182829november2018naplesitaly AT marcomerlano perspectivesinimmunotherapymeetingreportfromtheimmunotherapybridge20182829november2018naplesitaly AT paulnathan perspectivesinimmunotherapymeetingreportfromtheimmunotherapybridge20182829november2018naplesitaly AT kunleodunsi perspectivesinimmunotherapymeetingreportfromtheimmunotherapybridge20182829november2018naplesitaly AT hidehookada perspectivesinimmunotherapymeetingreportfromtheimmunotherapybridge20182829november2018naplesitaly AT chrystalmpaulos perspectivesinimmunotherapymeetingreportfromtheimmunotherapybridge20182829november2018naplesitaly AT sandropignata perspectivesinimmunotherapymeetingreportfromtheimmunotherapybridge20182829november2018naplesitaly AT kurtaschalper perspectivesinimmunotherapymeetingreportfromtheimmunotherapybridge20182829november2018naplesitaly AT stefanispranger perspectivesinimmunotherapymeetingreportfromtheimmunotherapybridge20182829november2018naplesitaly AT giampaolotortora perspectivesinimmunotherapymeetingreportfromtheimmunotherapybridge20182829november2018naplesitaly AT hassanezarour perspectivesinimmunotherapymeetingreportfromtheimmunotherapybridge20182829november2018naplesitaly AT lisahbutterfield perspectivesinimmunotherapymeetingreportfromtheimmunotherapybridge20182829november2018naplesitaly AT igorpuzanov perspectivesinimmunotherapymeetingreportfromtheimmunotherapybridge20182829november2018naplesitaly |